Cargando…

Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease

Parkinson’s disease is the second most prevalent neurodegenerative disorder in the Western world. It is estimated that the neuronal loss related to Parkinson’s disease precedes the clinical diagnosis by more than 10 years (prodromal phase) which leads to a subtle decline that translates into non-spe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peña-Nogales, Óscar, Ellmore, Timothy M., de Luis-García, Rodrigo, Suescun, Jessika, Schiess, Mya C., Giancardo, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333847/ https://www.ncbi.nlm.nih.gov/pubmed/30686966 http://dx.doi.org/10.3389/fnins.2018.00967

Ejemplares similares

Toward a Multimodal Computer-Aided Diagnostic Tool for Alzheimer’s Disease Conversion
por: Pena, Danilo, et al.
Publicado: (2022)

A Study of the Relationship Between Uric Acid and Substantia Nigra Brain Connectivity in Patients With REM Sleep Behavior Disorder and Parkinson's Disease
por: Ellmore, Timothy M., et al.
Publicado: (2020)

Quantifying Neurodegenerative Progression With DeepSymNet, an End-to-End Data-Driven Approach
por: Pena, Danilo, et al.
Publicado: (2019)

Updated Parkinson's disease motor subtypes classification and correlation to cerebrospinal homovanillic acid and 5-hydroxyindoleacetic acid levels
por: Adams, Christopher, et al.
Publicado: (2023)

Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease
por: Schiess, Mya, et al.
Publicado: (2021)

Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease
por: Suarez-Cedeno, Gerson, et al.
Publicado: (2017)

Computational medication regimen for Parkinson’s disease using reinforcement learning
por: Kim, Yejin, et al.
Publicado: (2021)

CSF from Parkinson disease Patients Differentially Affects Cultured Microglia and Astrocytes
por: Schiess, Mya C, et al.
Publicado: (2010)

Prodromal Markers in Parkinson’s Disease: Limitations in Longitudinal Studies and Lessons Learned
por: Heinzel, Sebastian, et al.
Publicado: (2016)

IgA-Biome Profiles Correlate with Clinical Parkinson’s Disease Subtypes
por: Brown, Eric L., et al.
Publicado: (2023)

Clinical and Imaging Markers of Prodromal Parkinson's Disease
por: Hustad, Eldbjørg, et al.
Publicado: (2020)

Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study
por: DuPont, Herbert L., et al.
Publicado: (2023)

Prodromal Markers of Parkinson's Disease in Patients With Essential Tremor
por: Wang, Xi-Xi, et al.
Publicado: (2020)

Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
por: Dommershuijsen, Lisanne J., et al.
Publicado: (2020)

The prodromes of Parkinson's disease
por: Rees, Richard Nathaniel, et al.
Publicado: (2018)

Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease
por: De Groote, Evelien, et al.
Publicado: (2020)

Bayesian network modeling of risk and prodromal markers of Parkinson’s disease
por: Sood, Meemansa, et al.
Publicado: (2023)

The Concept of Prodromal Parkinson’s Disease
por: Mahlknecht, Philipp, et al.
Publicado: (2015)

Editorial: Prodromal Parkinson's Disease
por: Crosiers, David, et al.
Publicado: (2021)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Slowed Prosaccades and Increased Antisaccade Errors As a Potential Behavioral Biomarker of Multiple System Atrophy
por: Brooks, Sarah H., et al.
Publicado: (2017)

Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients
por: Baldelli, Luca, et al.
Publicado: (2021)

Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective
por: Vermeiren, Yannick, et al.
Publicado: (2020)

Animal Model for Prodromal Parkinson’s Disease
por: Taguchi, Tomoyuki, et al.
Publicado: (2020)

Diagnostic Criteria for Parkinson’s Disease: From James Parkinson to the Concept of Prodromal Disease
por: Marsili, Luca, et al.
Publicado: (2018)

Prodromal non-motor symptoms of Parkinson’s disease
por: Pellicano, Clelia, et al.
Publicado: (2007)

The Microbiome-Mitochondria Dance in Prodromal Parkinson’s Disease
por: Cardoso, Sandra M., et al.
Publicado: (2018)

Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease
por: Meles, Sanne K., et al.
Publicado: (2021)

Prodromal Cognitive Deficits and the Risk of Subsequent Parkinson’s Disease
por: Speelberg, Daniël H. B., et al.
Publicado: (2022)

Prodromal and advanced non-motor features of Parkinson’s disease
por: Kempster, Peter
Publicado: (2021)

Neuropathology of incidental Lewy body & prodromal Parkinson’s disease
por: Koeglsperger, Thomas, et al.
Publicado: (2023)

Identifying prodromal symptoms at high specificity for Parkinson’s disease
por: Jackson, Holly, et al.
Publicado: (2023)

α-Synuclein and Anti-α-Synuclein Antibodies in Parkinson’s Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls
por: Smith, Lynnae M., et al.
Publicado: (2012)

The Myelin‐Weighted Connectome in Parkinson's Disease
por: Boshkovski, Tommy, et al.
Publicado: (2021)

Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder
por: Barber, Thomas R, et al.
Publicado: (2017)

Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study
por: Koros, Christos, et al.
Publicado: (2023)

Variation in Recent Onset Parkinson’s Disease: Implications for Prodromal Detection
por: Swallow, Diane M.A., et al.
Publicado: (2016)

Prevalence and duration of non‐motor symptoms in prodromal Parkinson's disease
por: Durcan, R., et al.
Publicado: (2019)

A comparison of prediction approaches for identifying prodromal Parkinson disease
por: Warden, Mark N., et al.
Publicado: (2021)

Prodromal Parkinson's disease: hype or hope for disease-modification trials?
por: Mahlknecht, Philipp, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tsinc749lmata9i4vvq9t8vsln